S&P TEST

SWOT & PESTLE.com

GILEAD SCIENCES SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. Topurchase reprints of this document, please email support@swotandpestle.com.



Company Name: Gilead Sciences

Company Sector: Pharmaceutics and Biotechnology

Operating Geography: United States, North America, Global

About the Company:

Gilead Sciences, Inc. is an American biopharmaceutical company that focuses primarily on antiviral drugs used in the treatment of Hepatitis B, Hepatitis C, HIV and influenza, including Sovaldi and Harvoni. It is headquartered at Foster City, California, United States. It was founded in June 1987 by Michael L. Riordan with the help of three core scientific advisers, Peter Dervan (Caltech), Doug Melton (Harvard) and Harold M. Weintraub (Fred Hutchinson Cancer Research Centre). The company has expanded to multiple drug segments through a series of strategic acquisitions starting from NeXstar Pharmaceuticals, Corus Pharma Inc. (2006), Raylo Chemicals Inc. (2006), CV Therapeutics (2009), CGI Pharmaceuticals (2010). The company's product portfolio includes more than 25 products including complete treatment regiments for HIV and Hepatitis C virus. Gilead was '2021 Facility of the Year Awards' winner for operational agility: COVID-19 impact. In August 2022, Gilead Sciences and MiroBio, a privately held biotechnology company based in the United Kingdom, signed a definitive deal under which Gilead will purchase MiroBio for about \$405 million in cash. MiroBio's exclusive discovery technology and comprehensive portfolio of immune inhibitory receptor agonists will be acquired by Gilead. As of 2023, Gilead has commercial sales operations in the US and globally, with subsidiaries in 35+ countries. Gilead's global workforce of over 16,000 employees across six continents is dedicated to improving global healthcare and fostering a better, healthier world.

The USP of Gilead Sciences lies in it being the market leader for HIV drugs globally. Gilead Sciences mission statement reads "To discover, develop and commercialize innovative therapeutics in the areas of unmet medical needs that improve patient care." The research based; biopharmaceutical company's vision is "To advance therapeutics against life-threatening diseases worldwide."

Revenue:

US\$27.2 billion – FY ending 31st December 2022 (y-o-y decline of 0.09%)

US\$27.3 billion – FY ending 31st December 2021 (y-o-y growth of 11%)

US\$24.6 billion - FY ending 31st December 2020



SWOT Analysis:

The SWOT Analysis for Gilead Sciences is given below:

Strengths	Weaknesses
1.Strong Brand Portfolio	1.Inability to accurately predict demand
2.Research and Development Orientation	2.Declining product sales in HIV and HCV
3.Investments in process automation	segment
4.Strategic Acquisitions and mergers	3.Reliance on three wholesalers for marketing
	and distribution
Opportunities	Threats
1. High growth potential of the	1.Certain challenges related to patent
biopharmaceutical industry	protection
2.Usage of Industry 4.0 technology	2.Regulation of manufacturing process
3.Expansion of footprint in various regions	3.Complexity of biopharma supply chain and
4.Acquires XinThera to enhance oncology and	operations
inflammation pipeline	4.High competition in the industry
5.Expands collaboration for inflammatory	5.Rising cases of counterfeit products
disease therapies	6.AIDS advocates pressure company over drug
	pricing



PESTLE Analysis:

The PESTLE Analysis for Gilead Sciences is given below:


Political	Economical
1.Impact of government legislative and	1.Fluctuations in the foreign currency
regulatory actions	exchange rate
2.Compliance with FDA and other comparable	2.Interest rate and credit risk on company's
international standards	portfolio
3.Political advantage due to the joint venture	3.Impact of inflation reduction act
with European Commission for Covid-19	
treatment	
4.Impact of Russia-Ukraine war	
5.Reimbursement pressures from government	
agencies	
Social	Technological
1.Impact of aging population	1.Opportunities due to emerging innovations
2.Contribution of the pharma industries	2.Risks associated with cyber security
towards the treatment of Covid-19	3.Revolutionizing healthcare- recent
3.Impact of public perception, awareness, and	advancements and key innovations
social stigma on disease awareness	
Legal	Environmental
1.Non-infringement of patents and proprietary	1.Green and Sustainable chemistry
rights	2.Waste Reduction and Recycling
2.Expensive litigation and government investigations	

Please note that our free summary reports contain the SWOT and PESTLE table contents only.

The complete report for **Gilead Sciences** SWOT & PESTLE Analysis is a paid report at **12.53 U.S.D.**



* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."



Copyright Notice

The information provided in the SWOT and PESTLE research reports on www.swotandpestle.com are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2024 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support: support@swotandpestle.com